Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Int J Mol Sci ; 21(17)2020 Aug 27.
Artigo em Inglês | MEDLINE | ID: mdl-32867307

RESUMO

Outside of Mycobacterium tuberculosis and Mycobacterium leprae, nontuberculous mycobacteria (NTM) are environmental mycobacteria (>190 species) and are classified as slow- or rapid-growing mycobacteria. Infections caused by NTM show an increased incidence in immunocompromised patients and patients with underlying structural lung disease. The true global prevalence of NTM infections remains unknown because many countries do not require mandatory reporting of the infection. This is coupled with a challenging diagnosis and identification of the species. Current therapies for treatment of NTM infections require multidrug regimens for a minimum of 18 months and are associated with serious adverse reactions, infection relapse, and high reinfection rates, necessitating discovery of novel antimycobacterial agents. Robust drug discovery processes have discovered inhibitors targeting mycobacterial membrane protein large 3 (MmpL3), a protein responsible for translocating mycolic acids from the inner membrane to periplasm in the biosynthesis of the mycobacterial cell membrane. This review focuses on promising new chemical scaffolds that inhibit MmpL3 function and represent interesting and promising putative drug candidates for the treatment of NTM infections. Additionally, agents (FS-1, SMARt-420, C10) that promote reversion of drug resistance are also reviewed.


Assuntos
Antibacterianos/farmacologia , Proteínas de Membrana Transportadoras/metabolismo , Infecções por Mycobacterium não Tuberculosas/tratamento farmacológico , Micobactérias não Tuberculosas/metabolismo , Antibacterianos/uso terapêutico , Proteínas de Bactérias/metabolismo , Transporte Biológico/efeitos dos fármacos , Descoberta de Drogas , Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos , Regulação Bacteriana da Expressão Gênica/efeitos dos fármacos , Humanos , Iodóforos/farmacologia , Iodóforos/uso terapêutico , Isoxazóis/farmacologia , Isoxazóis/uso terapêutico , Infecções por Mycobacterium não Tuberculosas/metabolismo , Ácidos Micólicos/metabolismo , Micobactérias não Tuberculosas/efeitos dos fármacos , Polissacarídeos/farmacologia , Polissacarídeos/uso terapêutico , Compostos de Espiro/farmacologia , Compostos de Espiro/uso terapêutico
2.
Microbiology (Reading) ; 166(5): 474-483, 2020 05.
Artigo em Inglês | MEDLINE | ID: mdl-32100712

RESUMO

Mycobacterium hassiacum is so far the most thermophilic among mycobacteria as it grows optimally at 50 °C and up to 65 °C in a glycerol-based medium, as verified in this study. Since this and other nontuberculous mycobacteria (NTM) thrive in diverse natural and artificial environments, from where they may access and infect humans, we deemed essential to probe M. hassiacum resistance to heat, a strategy routinely used to control microbial growth in water-supply systems, as well as in the food and drink industries. In addition to possibly being a threat in its own right in rare occasions, M. hassiacum is also a good surrogate for studying other NTM species more often associated with opportunistic infection, namely Mycobacterium avium and Mycobacterium abscessus as well as their strictly pathogenic counterparts Mycobacterium tuberculosis and Mycobacterium leprae. In this regard, this thermophilic species is likely to be useful as a source of stable proteins that may provide more detailed structures of potential drug targets. Here, we investigate M. hassiacum growth at near-pasteurization temperatures and at different pHs and also characterize its thermostable glucosyl-3-phosphoglycerate synthase (GpgS), an enzyme considered essential for M. tuberculosis growth and associated with both nitrogen starvation and thermal stress in different NTM species.


Assuntos
Proteínas de Bactérias/metabolismo , Glucosiltransferases/metabolismo , Mycobacteriaceae/crescimento & desenvolvimento , Mycobacteriaceae/genética , Proteínas de Bactérias/genética , DNA Bacteriano/genética , Glucosiltransferases/genética , Concentração de Íons de Hidrogênio , Mycobacteriaceae/metabolismo , Micobactérias não Tuberculosas/genética , Micobactérias não Tuberculosas/crescimento & desenvolvimento , Micobactérias não Tuberculosas/metabolismo , Pasteurização , Temperatura
3.
Microbiology (Reading) ; 153(Pt 12): 4159-4165, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18048929

RESUMO

Structural analysis of mycolic acids from Mycobacterium simiae (including some 'habana' strains) was carried out using (1)H-NMR and MS. Results indicated that this species presents a general pattern of alpha-, alpha'- and keto-mycolates. alpha-Mycolates were composed of a complex mixture of 82 to 89 carbon atoms (C82-C89), with the predominant molecular species containing two di-substituted cyclopropane rings. Among keto-mycolates (C84-C89), those containing one trans di-substituted cyclopropane ring were the most abundant. The alpha'-mycolates were monounsaturated (C64, C66). According to MS and (1)H-NMR data, the strains studied differed in fine structural details of alpha-mycolates and keto-mycolates. Notably, strain 'habana' TMC 5135 (belonging to the 'habana' group, and considered as highly immunogenic in tuberculosis and leprosy) presented a particular composition of alpha-mycolates, with a major component (C87) containing one cis plus one trans di-substituted cyclopropane ring, unlike the type strain of M. simiae and other strains of the 'habana' group (IPK-220 and IPK-337R), in which the major component (C84) contained two cis di-substituted cyclopropane rings. In spite of this finding, the 'habana' strains were closely related to each other and mainly differed from the type strain of M. simiae in some details of the fine structure of keto-mycolates. The present work indicated that within an identical general pattern of mycolic acids, there is a complex composition in M. simiae and structural variation among different strains, as reported for pathogenic species of the genus. Noteworthy was the particular composition of alpha-mycolates in strain 'habana' TMC 5135.


Assuntos
Ácidos Micólicos/química , Ácidos Micólicos/imunologia , Micobactérias não Tuberculosas/metabolismo , Animais , Vacinas Bacterianas/imunologia , Humanos , Hanseníase/imunologia , Hanseníase/prevenção & controle , Espectroscopia de Ressonância Magnética , Espectrometria de Massas , Especificidade da Espécie , Vacinas contra a Tuberculose/imunologia
5.
Acta Leprol ; 7 Suppl 1: 81-4, 1989.
Artigo em Inglês | MEDLINE | ID: mdl-2504012

RESUMO

Earlier work from this and other laboratories has revealed the presence within Mycobacterium spp. of three classes of glycolipid antigens which we have called the glycopeptidolipids, the lipooligosaccharides and the phenolic glycolipids. Representative structures of each from different species and sub-species have been proposed. More recently, new variants of these antigens and older structures have been analyzed by Fourier transform infrared, NMR, particularly at high temperatures, and, most notably, by fast atom bombardment and Californium desorption mass spectrometry. Extraordinary novelty and diversity were revealed, particularly at the distal non-reducing end of the oligosaccharide chains, marked by the presence of new branched-chain sugars, amino sugars and sugar acids. These epitopes and monoclonal antibodies to them have been used for the critical identification of mycobacteria. In addition, the pure antigens are the basis of specific serological tests for various mycobacterioses. The resurgence of interest in "atypical" mycobacteria stems from their occurrence as opportunistic pathogens in many patients with acquired immunodeficiency syndrome, although they have long been associated with pulmonary and other organ infections. Foremost among these mycobacteria are serovars of the Mycobacterium avium-Mycobacterium intracellulare complex (the M. avium complex). The surface antigens which differentiate these serovars are glycopeptidolipids, related to "mycoside C" and, accordingly, composed of a glycosylated lipopeptide "core", fatty acyl-D-Phe-D-alloThr-D-Ala-L-acanyl-O- (3,4-di-O-methyl-alpha-L-rhamnopyranoside), to which a haptenic oligosaccharide is linked at the threonine substituent; this oligoglycosyl unit is the source of type specificity.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Glicolipídeos/metabolismo , Mycobacterium/metabolismo , Animais , Antígenos de Bactérias , Glicolipídeos/classificação , Glicolipídeos/imunologia , Humanos , Mycobacterium/imunologia , Infecções por Mycobacterium/diagnóstico , Micobactérias não Tuberculosas/imunologia , Micobactérias não Tuberculosas/metabolismo , Testes Sorológicos , Relação Estrutura-Atividade
6.
Rio de Janeiro; s.n; s.d. 8 p. ilus.
Não convencional em Português | LILACS, Sec. Est. Saúde SP, HANSEN, Hanseníase, SESSP-ILSLACERVO, Sec. Est. Saúde SP | ID: biblio-1241985

RESUMO

Os AA selecionaram doentes de lepra internados no Hospital Colonia Curupaiti e Hopsital Frei Antonio do Estado da Guanabara, Brasil, para experimentação da atividade antilepra do G 30 320. Todos oos pacinetes são da forma lepromatosa graus L1, L2,L3 e dimorfos, classificados nos seguinte Grupos:I - Doentes novos, virgens de tratamentoII - Doentes sulfono-resistentes com lepra progressiva avançadaIII - Doentes sujeitos a reação tipo ENL, talidomido dependentes. Desencadeia-se a reação sempre que se instituti tratamento sulfonico sem a respectiva e continua cobertura com talidomidaIV - Doentes talidomida insensiveis sujeitos a reação de ENI incontrolavel pelos metodos tradicionais inclusive talidomidaA experiencia tem por objetivo a verificação da utilidade do novo produito G 30 320 no controle do desenvvolvimento da Hanseniase e da reação leprotica. O esquema basico de administração tem sido 2 capisulas por dia durante 7 dias reduzindo-se então para l capsula diaria. Cada capsula contem l00 mg. de um derivado anilino aposafraninado G 30 320...


Assuntos
Humanos , Hanseníase/enzimologia , Hanseníase/epidemiologia , Hanseníase/reabilitação , Hanseníase/terapia , Micobactérias não Tuberculosas/genética , Micobactérias não Tuberculosas/imunologia , Micobactérias não Tuberculosas/isolamento & purificação , Micobactérias não Tuberculosas/metabolismo , Micobactérias não Tuberculosas/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA